Clinical and molecular diagnosis of pathologic complete response in rectal cancer

References

• Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40
   PubMed Web of Science ®Google Scholar
• Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010;11:835-44
   PubMed Web of Science ®Google Scholar
• Habr-Gama A, Perez RO, Nadalin W, et al. Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. J Gastrointest Surg 2005;9:90-9
   PubMed Web of Science ®Google Scholar
• Park IJ, You YN, Agarwal A, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol 2012;30:1770-6
   PubMed Web of Science ®Google Scholar
• Habr-Gama A, Perez RO, Sao Juliao et al. Nonoperative approaches to rectal cancer: a critical evaluation. Semin Radiat Oncol 2011;21:234-9
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R, Hughes R. Critical appraisal of the “wait and see” approach in rectal cancer for clinical complete responders after chemoradiation. Br J Surg 2012;99:897-909
   PubMed Web of Science ®Google Scholar
• Hiotis SP, Weber SM, Cohen AM, et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg 2002;194:131-5
   PubMed Web of Science ®Google Scholar
• Panganiban RA, Snow AL, Day RM. Mechanisms of radiation toxicity in transformed and non-transformed cells. Int J Mol Sci 2013;14:15931-58
   PubMed Web of Science ®Google Scholar
• Prise KM, Schettino G, Folkard M, Held KD. New insights on cell death from radiation exposure. Lancet Oncol 2005;6:520-8
   PubMed Web of Science ®Google Scholar
• Smith FM, Chang KH, Sheahan K, et al. The surgical significance of residual mucosal abnormalities in rectal cancer following neoadjuvant chemoradiotherapy. Br J Surg 2012;99:993-1001
   PubMed Web of Science ®Google Scholar
• Das P, Skibber JM, Rodriguez-Bigas MA, et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer 2007;109:1750-5
   PubMed Web of Science ®Google Scholar
• Park CH, Kim HC, Cho YB, et al. Predicting tumor response after preoperative chemoradiation using clinical parameters in rectal cancer. World J Gastroenterol 2011;17:5310-16
   PubMed Web of Science ®Google Scholar
• Garland ML, Vather R, Bunkley N, et al. Clinical tumour size and nodal status predict pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Int J Colorectal Dis 2014;29:301-7
   PubMed Web of Science ®Google Scholar
• Kuo LJ, Chern MC, Tsou MH, et al. Interpretation of magnetic resonance imaging for locally advanced rectal carcinoma after preoperative chemoradiation therapy. Dis Colon Rectum 2005;48:23-8
   PubMed Web of Science ®Google Scholar
• Shanmugan S, Arrangoiz R, Nitzkorski JR, et al. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT. Ann Surg Oncol 2012;19:2178-85
   PubMed Web of Science ®Google Scholar
• Perez RO, Habr-Gama A, Sao Juliao GP, et al. Predicting complete response to neoadjuvant CRT for distal rectal cancer using sequential PET/CT imaging. Tech Coloproctol 2014;18:699-708
   PubMed Web of Science ®Google Scholar
• Sun W, Xu J, Hu W, et al. The role of sequential 18(F) -FDG PET/CT in predicting tumour response after preoperative chemoradiation for rectal cancer. Colorectal Dis 2013;15:e231-8
   PubMed Web of Science ®Google Scholar
• van Stiphout RG, Lammering G, Buijsen J, et al. Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging. Radiother Oncol 2011;98:126-33
   PubMed Web of Science ®Google Scholar
• Gu J, Khong PL, Wang S, et al. Quantitative assessment of diffusion-weighted MR imaging in patients with primary rectal cancer: correlation with FDG-PET/CT. Mol Imaging Biol 2011;13:1020-8
   PubMed Web of Science ®Google Scholar
• Garcia-Aguilar J, Smith DD, Avila K, et al. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg 2011;254:97-102
   PubMed Web of Science ®Google Scholar
• Glimelius B. Optimal Time Intervals between Pre-Operative Radiotherapy or Chemoradiotherapy and Surgery in Rectal Cancer? Front Oncol 2014;4:50
   PubMedGoogle Scholar
• Tulchinsky H, Shmueli E, Figer A, et al. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol 2008;15:2661-7
   PubMed Web of Science ®Google Scholar
• de Campos-Lobato LF, Geisler DP, da Luz MA, et al. Neoadjuvant therapy for rectal cancer: the impact of longer interval between chemoradiation and surgery. J Gastrointest Surg 2011;15:444-50
   PubMed Web of Science ®Google Scholar
• Kalady MF, de Campos-Lobato LF, Stocchi L, et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg 2009;250:582-9
   PubMed Web of Science ®Google Scholar
• Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999;17:2396
   PubMed Web of Science ®Google Scholar
• Perez RO, Habr-Gama A, Sao Juliao GP, et al. Optimal timing for assessment of tumor response to neoadjuvant chemoradiation in patients with rectal cancer: do all patients benefit from waiting longer than 6 weeks? Int J Radiat Oncol Biol Phys 2012;84:1159-65
   PubMed Web of Science ®Google Scholar
• Wolthuis AM, Penninckx F, Haustermans K, et al. Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome. Ann Surg Oncol 2012;19:2833-41
   PubMed Web of Science ®Google Scholar
• Garcia-Aguilar J, Chow OS, Smith DD, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol 2015;16:957-966
   PubMed Web of Science ®Google Scholar
• Sloothaak DA, Geijsen DE, van Leersum NJ, et al. Dutch Surgical Colorectal Audit. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg 2013;100:933-9
   PubMed Web of Science ®Google Scholar
• Petrelli F, Sgroi G, Sarti E, Barni S. Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-Analysis of Published Studies. Ann Surg 2013; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Dolinsky CM, Mahmoud NN, Mick R, et al. Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer. J Surg Oncol 2007;96:207-12
   PubMed Web of Science ®Google Scholar
• Lim SB, Choi HS, Jeong SY, et al. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers. Ann Surg 2008;248:243-51
   PubMed Web of Science ®Google Scholar
• Stein DE, Mahmoud NN, Anne PR, et al. Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma. Dis Colon Rectum 2003;46:448-53
   PubMed Web of Science ®Google Scholar
• Probst CP, Becerra AZ, Aquina CT, et al. Extended Intervals after Neoadjuvant Therapy in Locally Advanced Rectal Cancer: The Key to Improved Tumor Response and Potential Organ Preservation. J Am Coll Surg 2015;221:430-40
   PubMed Web of Science ®Google Scholar
• Huerta S, Gao X, Saha D. Mechanisms of resistance to ionizing radiation in rectal cancer. Expert Rev Mol Diagn 2009;9:469-80
   PubMed Web of Science ®Google Scholar
• Ramzan Z, Nassri AB, Huerta S. Genotypic characteristics of resistant tumors to pre-operative ionizing radiation in rectal cancer. World J Gastrointest Oncol 2014;6:194-210
   PubMed Web of Science ®Google Scholar
• Komuro Y, Watanabe T, Hosoi Y, et al. The expression pattern of Ku correlates with tumor radiosensitivity and disease free survival in patients with rectal carcinoma. Cancer 2002;95:1199-205
   PubMed Web of Science ®Google Scholar
• Yoo S, Dynan WS. Geometry of a complex formed by double strand break repair proteins at a single DNA end: recruitment of DNA-PKcs induces inward translocation of Ku protein. Nucleic Acids Res 1999;27:4679-86
   PubMed Web of Science ®Google Scholar
• Someya M, Sakata K, Matsumoto Y, et al. The association of DNA-dependent protein kinase activity with chromosomal instability and risk of cancer. Carcinogenesis 2006;27:117-22
   PubMed Web of Science ®Google Scholar
• Adell G, Sun XF, Stal O, et al. p53 status: an indicator for the effect of preoperative radiotherapy of rectal cancer. Radiother Oncol 1999;51:169-74
   PubMed Web of Science ®Google Scholar
• Hur H, Kim NK, Min BS, et al. Can a biomarker-based scoring system predict pathologic complete response after preoperative chemoradiotherapy for rectal cancer? Dis Colon Rectum 2014;57:592-601
   PubMed Web of Science ®Google Scholar
• Chen Z, Duldulao MP, Li W, et al. Molecular diagnosis of response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer. J Am Coll Surg 2011;212:1008-17
   PubMed Web of Science ®Google Scholar
• Garcia VM, Batlle JF, Casado E, et al. Immunohistochemical analysis of tumour regression grade for rectal cancer after neoadjuvant chemoradiotherapy. Colorectal Dis 2011;13:989-98
   PubMed Web of Science ®Google Scholar
• Nehls O, Klump B, Holzmann K, et al. Influence of p53 status on prognosis in preoperatively irradiated rectal carcinoma. Cancer 1999;85:2541-8
   PubMed Web of Science ®Google Scholar
• Chen MB, Wu XY, Yu R, et al. P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer. PLoS One 2012;7:e45388
   PubMed Web of Science ®Google Scholar
• Qiu H, Sirivongs P, Rothenberger M, et al. Molecular prognostic factors in rectal cancer treated by radiation and surgery. Dis Colon Rectum 2000;43:451-9
   PubMed Web of Science ®Google Scholar
• Lin LC, Lee HH, Hwang WS, et al. p53 and p27 as predictors of clinical outcome for rectal-cancer patients receiving neoadjuvant therapy. Surg Oncol 2006;15:211-16
   PubMed Web of Science ®Google Scholar
• Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997;12:19-23
   PubMed Web of Science ®Google Scholar
• Huerta S, Gao X, Dineen S, et al. Role of p53, Bax, p21, and DNA-PKcs in radiation sensitivity of HCT-116 cells and xenografts. Surgery 2013;154:143-51
   PubMed Web of Science ®Google Scholar
• Flanagan L, Kehoe J, Fay J, et al. High levels of X-linked Inhibitor-of-Apoptosis Protein (XIAP) are indicative of radio chemotherapy resistance in rectal cancer. Radiat Oncol 2015;10:131
   PubMed Web of Science ®Google Scholar
• Toiyama Y, Inoue Y, Saigusa S, et al. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery. Clin Oncol (R Coll Radiol) 2010;22:272-80
   PubMed Web of Science ®Google Scholar
• Lim SH, Chua W, Henderson C, et al. Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Crit Rev Oncol Hematol 2015. [Epub ahead of print]
   Google Scholar
• Debucquoy A, Goethals L, Libbrecht L, et al. Molecular and clinico-pathological markers in rectal cancer: a tissue micro-array study. Int J Colorectal Dis 2009;24:129-38
   PubMed Web of Science ®Google Scholar
• Huerta S, Hrom J, Gao X, et al. Tissue microarray constructs to predict a response to chemoradiation in rectal cancer. Dig Liver Dis 2010;42:679-84
   PubMedGoogle Scholar
• Palma P, Cuadros M, Conde-Muino R, et al. Microarray profiling of mononuclear peripheral blood cells identifies novel candidate genes related to chemoradiation response in rectal cancer. PLoS One 2013;8:e74034
   PubMed Web of Science ®Google Scholar
• Palma P, Cano C, Conde-Muino R, et al. Expression profiling of rectal tumors defines response to neoadjuvant treatment related genes. PLoS One 2014;9:e112189
   PubMed Web of Science ®Google Scholar
• Ghadimi BM, Grade M, Difilippantonio MJ, et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 2005;23:1826-38
   PubMed Web of Science ®Google Scholar
• Kim IJ, Lim SB, Kang HC, et al. Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer. Dis Colon Rectum 2007;50:1342-53
   PubMed Web of Science ®Google Scholar
• Rimkus C, Friederichs J, Boulesteix AL, et al. Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer. Clin Gastroenterol Hepatol 2008;6:53-61
   PubMed Web of Science ®Google Scholar
• Watanabe T, Komuro Y, Kiyomatsu T, et al. Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Res 2006;66:3370-4
   PubMed Web of Science ®Google Scholar
• Lopes-Ramos C, Koyama FC, Habr-Gama A, et al. Comprehensive evaluation of the effectiveness of gene expression signatures to predict complete response to neoadjuvant chemoradiotherapy and guide surgical intervention in rectal cancer. Cancer Genet 2015;208:319-26
   PubMed Web of Science ®Google Scholar
• Trapnell C, Williams BA, Pertea G, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 2010;28:511-15
   PubMed Web of Science ®Google Scholar
• Brettingham-Moore KH, Duong CP, Greenawalt DM, et al. Pretreatment transcriptional profiling for predicting response to neoadjuvant chemoradiotherapy in rectal adenocarcinoma. Clin Cancer Res 2011;17:3039-47
   PubMed Web of Science ®Google Scholar
• Ambros V. The functions of animal microRNAs. Nature 2004;431:350-5
   PubMed Web of Science ®Google Scholar
• Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev 2009;28:369-78
   PubMed Web of Science ®Google Scholar
• Della Vittoria SG, Falcetta F, Carlomagno C, et al. A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2012;83:1113-19
   PubMed Web of Science ®Google Scholar
• Kheirelseid EA, Miller N, Chang KH, et al. miRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy. Int J Colorectal Dis 2013;28:247-60
   PubMed Web of Science ®Google Scholar
• Lopes-Ramos CM, Habr-Gama A, Quevedo BS, et al. Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients. BMC Med Genomics 2014;7:68
   PubMed Web of Science ®Google Scholar
• Svoboda M, Sana J, Fabian P, et al. MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol 2012;7:195
   PubMed Web of Science ®Google Scholar
• Buijsen J, van Stiphout RG, Menheere PP, et al. Blood biomarkers are helpful in the prediction of response to chemoradiation in rectal cancer: a prospective, hypothesis driven study on patients with locally advanced rectal cancer. Radiother Oncol 2014;111:237-42
   PubMed Web of Science ®Google Scholar
• Yoon SM, Kim DY, Kim TH, et al. Clinical parameters predicting pathologic tumor response after preoperative chemoradiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2007;69:1167-72
   PubMed Web of Science ®Google Scholar
• Tural D, Selcukbiricik F, Ozturk MA, et al. The relation between pathological complete response and clinical outcome in patients with rectal cancer. Hepatogastroenterol 2013;60:1365-70
   PubMed Web of Science ®Google Scholar
• Park YA, Sohn SK, Seong J, et al. Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. J Surg Oncol 2006;93:145-50
   PubMed Web of Science ®Google Scholar
• Russo AL, Ryan DP, Borger DR, et al. Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer. J Gastrointest Cancer 2014;45:34-9
   PubMedGoogle Scholar
• Yang TJ, Goodman KA. Predicting complete response: is there a role for non-operative management of rectal cancer? J Gastrointest Oncol 2015;6:241-6
   PubMed Web of Science ®Google Scholar
• Perez RO, Sao Juliao GP, Habr-Gama A, et al. The role of carcinoembriogenic antigen in predicting response and survival to neoadjuvant chemoradiotherapy for distal rectal cancer. Dis Colon Rectum 2009;52:1137-43
   PubMed Web of Science ®Google Scholar
• Unger KR, Romney DA, Koc M, et al. Preoperative chemoradiation for rectal cancer using capecitabine and celecoxib correlated with posttreatment assessment of thymidylate synthase and thymidine phosphorylase expression. Int J Radiat Oncol Biol Phys 2011;80:1377-82
   PubMed Web of Science ®Google Scholar
• Jakob C, Aust DE, Meyer W, et al. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer. J Pathol 2004;204:562-8
   PubMed Web of Science ®Google Scholar
• Kikuchi M, Mikami T, Sato T, et al. High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction. Br J Cancer 2009;101:116-23
   PubMed Web of Science ®Google Scholar
• Barcellos-Hoff MH, Park C, Wright EG. Radiation and the microenvironment - tumorigenesis and therapy. Nat Rev Cancer 2005;5:867-75
   PubMed Web of Science ®Google Scholar
• Kitayama J, Yasuda K, Kawai K, et al. Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer. BMC Cancer 2011;11:64
   PubMed Web of Science ®Google Scholar
• Kitayama J, Yasuda K, Kawai K, et al. Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer. Radiat Oncol 2010;5:47
   PubMed Web of Science ®Google Scholar
• Yasuda K, Sunami E, Kawai K, et al. Laboratory blood data have a significant impact on tumor response and outcome in preoperative chemoradiotherapy for advanced rectal cancer. J Gastrointest Cancer 2012;43:236-43
   PubMedGoogle Scholar
• Heo J, Chun M, Noh OK, et al. Sustaining Blood Lymphocyte Count during Preoperative Chemoradiotherapy as a Predictive Marker for Pathologic Complete Response in Locally Advanced Rectal Cancer. Cancer Res Treat 2015; Epub ahead of print
   Google Scholar
• Dou X, Wang RB, Yan HJ, et al. Circulating lymphocytes as predictors of sensitivity to preoperative chemoradiotherapy in rectal cancer cases. Asian Pac J Cancer Prev 2013;14:3881-5
   PubMed Web of Science ®Google Scholar
• Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008;14:6735-41
   PubMed Web of Science ®Google Scholar
• Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 2010;103:861-9
   PubMed Web of Science ®Google Scholar
• Hu-Lieskovan S, Vallbohmer D, Zhang W, et al. EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. Clin Cancer Res 2011;17:5161-9
   PubMed Web of Science ®Google Scholar
• Chang DZ, Kumar V, Ma Y, et al. Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. J Hematol Oncol 2009;2:18
   PubMed Web of Science ®Google Scholar
• Clancy C, Burke JP, Coffey JC. KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis. Surg Oncol 2013;22:105-11
   PubMed Web of Science ®Google Scholar
• Pucciarelli S, Rampazzo E, Briarava M, et al. Telomere-specific reverse transcriptase (hTERT) and cell-free RNA in plasma as predictors of pathologic tumor response in rectal cancer patients receiving neoadjuvant chemoradiotherapy. Ann Surg Oncol 2012;19:3089-96
   PubMed Web of Science ®Google Scholar
• Zitt M, Zitt M, Muller HM, et al. Disseminated tumor cells in peripheral blood: a novel marker for therapy response in locally advanced rectal cancer patients undergoing preoperative chemoradiation. Dis Colon Rectum 2006;49:1484-91
   PubMed Web of Science ®Google Scholar
• Lam AK, Ong K, Ho YH. hTERT expression in colorectal adenocarcinoma: correlations with p21, p53 expressions and clinicopathological features. Int J Colorectal Dis 2008;23:587-94
   PubMed Web of Science ®Google Scholar
• Shin JS, Foo T, Hong A, et al. Telomerase expression as a predictive marker of radiotherapy response in rectal cancer. Pathology 2012;44:209-15
   PubMed Web of Science ®Google Scholar